• Je něco špatně v tomto záznamu ?

A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups

SK. Hoiseth, E. Murphy, L. Andrew, U. Vogel, M. Frosch, W. Hellenbrand, R. Abad, JA. Vazquez, R. Borrow, J. Findlow, MK. Taha, AE. Deghmane, DA. Caugant, P. Kriz, M. Musilek, LW. Mayer, X. Wang, JR. Macneil, L. York, CY. Tan, KU. Jansen, AS. Anderson,

. 2013 ; 32 (10) : 1096-101.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14064173

BACKGROUND: Recombinant vaccines containing factor H-binding protein (fHBP) have been developed for the purpose of protection from invasive meningococcal serogroup B disease. Neisseria meningitidis fHBP sequences can be divided into 2 genetically and immunologically distinct subfamilies (A and B); thus, cross protection is conferred within but not between subfamilies. A comprehensive understanding of fHBP epidemiology is required to accurately assess the potential vaccine impact when considering different vaccination implementation strategies. METHODS: Systematically collected invasive meningococcal serogroup B isolates from England, Wales, Northern Ireland, the United States, Norway, France and the Czech Republic were previously characterized for fHBP sequence. This study expanded the evaluation with additional meningococcal serogroup B disease isolates from Spain (n = 346) and Germany (n = 205). This expanded set (n = 1841), collected over a 6-year period (2001 to 2006), was evaluated for fHBP sequence and fHBP subfamily relative to patient age. RESULTS: All 1841 isolates contained fhbp. fHBP sequences from Spain and Germany fell within the previously described subfamilies, with 69% of isolates belonging to subfamily B and 31% to subfamily A; prevalent sequence variants were also similar. Stratification of data by age indicated that disease in infants <1 year of age was caused by a significantly higher proportion of isolates with fHBP subfamily A variants than that seen in adolescents and young adults 11-25 years (47.7% versus 19.5%, P < 0.0001, respectively). CONCLUSIONS: These observations highlight a difference in epidemiology of fHBP subfamilies in different age groups, with fHBP subfamily A strains causing more disease in vulnerable populations, such as infants, than in adolescents.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14064173
003      
CZ-PrNML
005      
20140708091141.0
007      
ta
008      
140704s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/INF.0b013e31829aa63b $2 doi
035    __
$a (PubMed)23694830
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hoiseth, Susan K $u From the *Pfizer Vaccine Research, Pearl River, NY; †Institute for Hygiene and Microbiology, University of Würzburg, Würzburg; ‡Robert Koch Institute, Berlin, Germany; §National Institute of Health, Carlos III, Madrid, Spain; ¶Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom; ‖Institut Pasteur, Paris, France; **Norwegian Institute of Public Health, Oslo, Norway; ††National Institute of Public Health, Prague, Czech Republic; ‡‡Centers for Disease Control and Prevention, Atlanta, GA; and §§Pfizer, Collegeville, PA.
245    12
$a A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups / $c SK. Hoiseth, E. Murphy, L. Andrew, U. Vogel, M. Frosch, W. Hellenbrand, R. Abad, JA. Vazquez, R. Borrow, J. Findlow, MK. Taha, AE. Deghmane, DA. Caugant, P. Kriz, M. Musilek, LW. Mayer, X. Wang, JR. Macneil, L. York, CY. Tan, KU. Jansen, AS. Anderson,
520    9_
$a BACKGROUND: Recombinant vaccines containing factor H-binding protein (fHBP) have been developed for the purpose of protection from invasive meningococcal serogroup B disease. Neisseria meningitidis fHBP sequences can be divided into 2 genetically and immunologically distinct subfamilies (A and B); thus, cross protection is conferred within but not between subfamilies. A comprehensive understanding of fHBP epidemiology is required to accurately assess the potential vaccine impact when considering different vaccination implementation strategies. METHODS: Systematically collected invasive meningococcal serogroup B isolates from England, Wales, Northern Ireland, the United States, Norway, France and the Czech Republic were previously characterized for fHBP sequence. This study expanded the evaluation with additional meningococcal serogroup B disease isolates from Spain (n = 346) and Germany (n = 205). This expanded set (n = 1841), collected over a 6-year period (2001 to 2006), was evaluated for fHBP sequence and fHBP subfamily relative to patient age. RESULTS: All 1841 isolates contained fhbp. fHBP sequences from Spain and Germany fell within the previously described subfamilies, with 69% of isolates belonging to subfamily B and 31% to subfamily A; prevalent sequence variants were also similar. Stratification of data by age indicated that disease in infants <1 year of age was caused by a significantly higher proportion of isolates with fHBP subfamily A variants than that seen in adolescents and young adults 11-25 years (47.7% versus 19.5%, P < 0.0001, respectively). CONCLUSIONS: These observations highlight a difference in epidemiology of fHBP subfamilies in different age groups, with fHBP subfamily A strains causing more disease in vulnerable populations, such as infants, than in adolescents.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a antigeny bakteriální $x analýza $x genetika $x imunologie $7 D000942
650    _2
$a bakteriální proteiny $x analýza $x genetika $x imunologie $7 D001426
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a meningokokové infekce $x epidemiologie $x imunologie $x mikrobiologie $x prevence a kontrola $7 D008589
650    _2
$a meningokokové vakcíny $x aplikace a dávkování $x imunologie $7 D022401
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Neisseria meningitidis $x chemie $x imunologie $x izolace a purifikace $7 D009345
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Spojené státy americké $x epidemiologie $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Murphy, Ellen
700    1_
$a Andrew, Lubomira $7 gn_A_00006582
700    1_
$a Vogel, Ulrich
700    1_
$a Frosch, Matthias
700    1_
$a Hellenbrand, Wiebke
700    1_
$a Abad, Raquel $7 gn_A_00000135
700    1_
$a Vazquez, Julio A
700    1_
$a Borrow, Ray
700    1_
$a Findlow, Jamie
700    1_
$a Taha, Muhamed-Kheir
700    1_
$a Deghmane, Ala-Eddine
700    1_
$a Caugant, Dominique A
700    1_
$a Kriz, Paula
700    1_
$a Musilek, Martin
700    1_
$a Mayer, Leonard W
700    1_
$a Wang, Xin
700    1_
$a Macneil, Jessica R
700    1_
$a York, Laura
700    1_
$a Tan, Charles Y
700    1_
$a Jansen, Kathrin U
700    1_
$a Anderson, Annaliesa S $7 gn_A_00006108
773    0_
$w MED00003732 $t The Pediatric infectious disease journal $x 1532-0987 $g Roč. 32, č. 10 (2013), s. 1096-101
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23694830 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708091431 $b ABA008
999    __
$a ok $b bmc $g 1031657 $s 862905
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 32 $c 10 $d 1096-101 $i 1532-0987 $m The Pediatric infectious disease journal $n Pediatr Infect Dis J $x MED00003732
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Možnosti archivace